The Impact of HER-2 Status on Local Recurrence in Women with Stage I?II Breast Cancer Treated with Breast-Conserving Therapy

Abstract

This study was undertaken to determine whether overexpression of the oncogene HER-2 is associated with an increase in local recurrence in women with early stage breast cancer treated with breast-conserving therapy (BCT). A retrospective review of the medical records of all women treated with stage I-II invasive breast cancer from 1991 through 2001 was performed. Of 596 eligible patients treated in that time period, immunohistochemical testing for HER-2 expression was performed in 352 patients (59%): 266 patients (76%) were HER-2 negative and 86 patients (24%) were HER-2 positive. Median follow-up was 5.4 years. The patient characteristics for the two groups were compared for age, pathologic T and N stage, number of positive nodes, estrogen receptor (ER) and progesterone receptor (PR) status, radiation treatment, and use of hormonal therapy or chemotherapy. There were no significant differences in any of these parameters between the two groups (all p > or = 0.10). Local recurrence at 5 years was 2% in the HER-2-negative group and 0% in the HER-2-positive group (p = 0.15). There was no difference in local recurrence after BCT between HER-2-positive and negative breast cancers at 5 years. Therefore HER-2 overexpression does not appear to be a contraindication to BCT.

Estrogen/Progesterone Receptor Negativity and HER2 Positivity Predict Locoregional Recurrence in Patients With T1a,bN0 Breast Cancer

“…That study did not include an assessment of margin status, a factor we found to be highly significant on multivariate analysis. Another study examined HER2 overexpression in tumors from 352 patients with stage I-II breast cancer treated with BCT and found no difference in the local recurrence rates between the HER2-positive and HER2-negative tumors (22). That study found very low recurrence rates in both the HER2-positive (0%) and the HER2-negative (2%) group.…”

Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study

“…The use of these three tumor markers to approximate biologic subtype has practical value in that these tumor markers are commonly available from retrospective data and guide the selection of targeted adjuvant systemic therapies (e.g., hormonal therapy, trastuzumab). Some studies have suggested an increased risk of local recurrence or local–regional recurrence after breast conservation treatment associated with the triple negative (basal-like) subtype or associated with tumors that are HER2 positive, although these associations have not been demonstrated uniformly in all studies [4–10, 23]. In the present study, no statistically significant differences in the 10-year rates of local recurrence or local– regional recurrence were observed based on biologic subtype (both P ≥ 0.76; Table 2; Fig.…”

Photodynamic therapy activated signaling from epidermal growth factor receptor and STAT3

“…Immunostaining was performed as previously described. 31,32 Briefly, cells were plated onto polyl-lysine Hydrobromide treated, flamed, glass coverslips in 4 cm dishes at 5 × 10 5 cells per dish and allowed to attach overnight. BPD-PDT was performed as described elsewhere in this paper, with dishes fixed at 5 and 60 min post illumination.…”